Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

A Novel CMY Variant Confers Transferable High-Level Resistance to Ceftazidime-Avibactam in Multidrug-Resistant Escherichiacoli

14 Feb 2023

Abstract excerpt

isolates producing AmpC, such as CMY-like cephalosporinase. However, in recent years, CMY variants have been reported to confer ceftazidime-avibactam resistance. We reported a novel CMY variant, CMY-178, that confers high-level ceftazidime-avibactam resistance with potent transferability. Therefore, this resistance gene is a tremendous potential menace to public health and needs attention of clinicians.

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Antibiotic Resistance in Bacteria
Share to Antibiotics Pharmacokinetics and Efficacy
Share to Plant Pathogenic Bacteria Studies

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Source

Identifiers

PMID: 36786629
DOI: 10.1128/spectrum.03349-22

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 2 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

A Novel CMY Variant Confers Transferable High-Level Resistance to Ceftazidime-Avibactam in Multidrug-Resistant EscherichiacoliPMID 36786629Read ↗

Novel plasmid-mediated CMY variant (CMY-192) conferring ceftazidime-avibactam resistance in multidrug-resistant Escherichia coliSemantic proximity Read ↗

High-level ceftazidime-avibactam resistance in <i>Escherichia coli</i> conferred by the novel plasmid-mediated beta-lactamase CMY-185 variantSemantic proximity Read ↗

High-level ceftazidime/avibactam resistance in Escherichia coli conferred by the novel plasmid-mediated β-lactamase CMY-185 variantSemantic proximity Read ↗

Structural insights into the molecular mechanism of high-level ceftazidime–avibactam resistance conferred by CMY-185Semantic proximity Read ↗

Aztreonam-avibactam: an option against carbapenem-resistant Enterobacterales with emerging resistanceSemantic proximity Read ↗

Dissemination of transferable AmpC-type beta-lactamase (CMY-10) in a Korean hospital.Semantic proximity Read ↗

Molecular characterization of AmpC-producing Escherichia coli clinical isolates recovered in a French hospitalSemantic proximity Read ↗

Characterization of the new AmpC β-lactamase FOX-8 reveals a single mutation, Phe313Leu, located in the R2 loop that affects ceftazidime hydrolysis.Semantic proximity Read ↗

Resistance to aztreonam-avibactam due to a mutation of SHV-12 in Enterobacter.Semantic proximity Read ↗

Structural Basis of Reduced Susceptibility to Ceftazidime-Avibactam and Cefiderocol in Enterobacter cloacae Due to AmpC R2 Loop DeletionSemantic proximity Read ↗

Naturally occurring extended-spectrum cephalosporinases in Escherichia coli.Semantic proximity Read ↗

Comparative characterization of the cephamycinase blaCMY-1 gene and its relationship with other beta-lactamase genes.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.